https://stock.noler.com/us/stock/inozyme-pharma-inc https://stock.noler.com/us/stock/inozyme-pharma-inc/accounts-payable https://stock.noler.com/us/stock/inozyme-pharma-inc/accretion-amortization-of-discounts-and-premiums-investments https://stock.noler.com/us/stock/inozyme-pharma-inc/accrued-liabilities-current https://stock.noler.com/us/stock/inozyme-pharma-inc/accrued-professional-fees-current https://stock.noler.com/us/stock/inozyme-pharma-inc/accumulated-depreciation https://stock.noler.com/us/stock/inozyme-pharma-inc/additional-paid-in-capital-common-stock https://stock.noler.com/us/stock/inozyme-pharma-inc/additions-to-other-assets-amount https://stock.noler.com/us/stock/inozyme-pharma-inc/allocated-share-based-compensation-expense https://stock.noler.com/us/stock/inozyme-pharma-inc/amortization-of-debt-discount-premium https://stock.noler.com/us/stock/inozyme-pharma-inc/antidilutive-securities-excluded-from-computation-of-earnings-per-share-amount https://stock.noler.com/us/stock/inozyme-pharma-inc/aoci https://stock.noler.com/us/stock/inozyme-pharma-inc/asset-impairment-charges https://stock.noler.com/us/stock/inozyme-pharma-inc/available-for-sale-debt-accumulated-gross-unrealized-gain-before-tax https://stock.noler.com/us/stock/inozyme-pharma-inc/available-for-sale-debt-accumulated-gross-unrealized-loss-before-tax https://stock.noler.com/us/stock/inozyme-pharma-inc/available-for-sale-debt-allowance-for-credit-loss https://stock.noler.com/us/stock/inozyme-pharma-inc/available-for-sale-debt-amortized-cost-basis https://stock.noler.com/us/stock/inozyme-pharma-inc/available-for-sale-debt-realized-gain-loss https://stock.noler.com/us/stock/inozyme-pharma-inc/available-for-sale-debt-securities https://stock.noler.com/us/stock/inozyme-pharma-inc/available-for-sale-debt-unrealized-gain-loss https://stock.noler.com/us/stock/inozyme-pharma-inc/available-for-sale-debt-unrealized-loss-position https://stock.noler.com/us/stock/inozyme-pharma-inc/available-for-sale-debt-unrealized-loss-position-12-months-or-longer-loss https://stock.noler.com/us/stock/inozyme-pharma-inc/available-for-sale-debt-unrealized-loss-position-less-than-12-months https://stock.noler.com/us/stock/inozyme-pharma-inc/basic-shares https://stock.noler.com/us/stock/inozyme-pharma-inc/capital-expenditures https://stock.noler.com/us/stock/inozyme-pharma-inc/capital-expenditures-incurred-but-not-yet-paid https://stock.noler.com/us/stock/inozyme-pharma-inc/cash https://stock.noler.com/us/stock/inozyme-pharma-inc/cash-and-cash-equivalents-change-excluding-exchange-rate-effect https://stock.noler.com/us/stock/inozyme-pharma-inc/cash-and-equivalents https://stock.noler.com/us/stock/inozyme-pharma-inc/cash-and-restricted-cash-change-excluding-exchange-rate-effect https://stock.noler.com/us/stock/inozyme-pharma-inc/cash-and-restricted-cash-including-disposal-group-and-discontinued-operations https://stock.noler.com/us/stock/inozyme-pharma-inc/cash-cash-equivalents-and-short-term-investments https://stock.noler.com/us/stock/inozyme-pharma-inc/cash-flow-breakdown https://stock.noler.com/us/stock/inozyme-pharma-inc/class-of-warrant-or-right-exercise-price-of-warrants-or-rights https://stock.noler.com/us/stock/inozyme-pharma-inc/common-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/inozyme-pharma-inc/common-stock-value https://stock.noler.com/us/stock/inozyme-pharma-inc/comprehensive-income https://stock.noler.com/us/stock/inozyme-pharma-inc/concept-stock-issued-tag-2 https://stock.noler.com/us/stock/inozyme-pharma-inc/conversion-of-stock-shares-converted https://stock.noler.com/us/stock/inozyme-pharma-inc/convertible-preferred-stock-shares-issued-upon-conversion https://stock.noler.com/us/stock/inozyme-pharma-inc/cover-page-shares-outstanding https://stock.noler.com/us/stock/inozyme-pharma-inc/current-assets https://stock.noler.com/us/stock/inozyme-pharma-inc/current-liabilities https://stock.noler.com/us/stock/inozyme-pharma-inc/debt-and-capital-lease-obligations https://stock.noler.com/us/stock/inozyme-pharma-inc/debt-carrying-amount https://stock.noler.com/us/stock/inozyme-pharma-inc/debt-interest-rate-stated-percentage https://stock.noler.com/us/stock/inozyme-pharma-inc/debt-issued https://stock.noler.com/us/stock/inozyme-pharma-inc/debt-unamortized-discount-premium-and-debt-issuance-costs-net https://stock.noler.com/us/stock/inozyme-pharma-inc/deferred-costs-current-and-noncurrent https://stock.noler.com/us/stock/inozyme-pharma-inc/deferred-finance-costs-noncurrent-net https://stock.noler.com/us/stock/inozyme-pharma-inc/deferred-income-tax-liabilities https://stock.noler.com/us/stock/inozyme-pharma-inc/deferred-rent-credit-current https://stock.noler.com/us/stock/inozyme-pharma-inc/deferred-tax-assets-gross https://stock.noler.com/us/stock/inozyme-pharma-inc/deferred-tax-assets-in-process-research-and-development https://stock.noler.com/us/stock/inozyme-pharma-inc/deferred-tax-assets-liabilities-net https://stock.noler.com/us/stock/inozyme-pharma-inc/deferred-tax-assets-net https://stock.noler.com/us/stock/inozyme-pharma-inc/deferred-tax-assets-operating-loss-carryforwards https://stock.noler.com/us/stock/inozyme-pharma-inc/deferred-tax-assets-other https://stock.noler.com/us/stock/inozyme-pharma-inc/deferred-tax-assets-stock-compensation https://stock.noler.com/us/stock/inozyme-pharma-inc/deferred-tax-assets-tax-credit-carryforwards-research https://stock.noler.com/us/stock/inozyme-pharma-inc/deferred-tax-assets-tax-deferred-expense-reserves-and-accruals-accrued-liabilities https://stock.noler.com/us/stock/inozyme-pharma-inc/deferred-tax-assets-tax-deferred-expense-reserves-and-accruals-deferred-rent https://stock.noler.com/us/stock/inozyme-pharma-inc/deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/inozyme-pharma-inc/deferred-tax-liabilities-deferred-expense-deferred-financing-costs https://stock.noler.com/us/stock/inozyme-pharma-inc/deferred-tax-liabilities-property-plant-and-equipment https://stock.noler.com/us/stock/inozyme-pharma-inc/defined-contribution-plan-employer-discretionary-contribution-amount https://stock.noler.com/us/stock/inozyme-pharma-inc/defined-contribution-plan-employer-matching-contribution-percent-of-match https://stock.noler.com/us/stock/inozyme-pharma-inc/depreciation https://stock.noler.com/us/stock/inozyme-pharma-inc/depreciation-and-amortization-expense https://stock.noler.com/us/stock/inozyme-pharma-inc/diluted-shares https://stock.noler.com/us/stock/inozyme-pharma-inc/dividends-declared https://stock.noler.com/us/stock/inozyme-pharma-inc/earnings-per-share-basic-and-diluted https://stock.noler.com/us/stock/inozyme-pharma-inc/effect-of-exchange-rate-on-cash-and-cash-equivalents https://stock.noler.com/us/stock/inozyme-pharma-inc/effective-tax-rate https://stock.noler.com/us/stock/inozyme-pharma-inc/employee-related-liabilities-current https://stock.noler.com/us/stock/inozyme-pharma-inc/eps https://stock.noler.com/us/stock/inozyme-pharma-inc/eps-basic https://stock.noler.com/us/stock/inozyme-pharma-inc/exchange-rate-effect-on-cash https://stock.noler.com/us/stock/inozyme-pharma-inc/fair-value-assets-level-1-to-level-2-transfers-amount https://stock.noler.com/us/stock/inozyme-pharma-inc/fair-value-assets-level-2-to-level-1-transfers-amount https://stock.noler.com/us/stock/inozyme-pharma-inc/finance-lease-impairment-loss https://stock.noler.com/us/stock/inozyme-pharma-inc/financing-cash-flow https://stock.noler.com/us/stock/inozyme-pharma-inc/foreign-currency-transaction-gain-loss-realized https://stock.noler.com/us/stock/inozyme-pharma-inc/form-d-stocks https://stock.noler.com/us/stock/inozyme-pharma-inc/gain-loss-on-sale-of-property-plant-equipment https://stock.noler.com/us/stock/inozyme-pharma-inc/general-and-administrative-expense https://stock.noler.com/us/stock/inozyme-pharma-inc/income-tax https://stock.noler.com/us/stock/inozyme-pharma-inc/income-tax-examination-penalties-and-interest-expense https://stock.noler.com/us/stock/inozyme-pharma-inc/increase-decrease-in-accounts-payable https://stock.noler.com/us/stock/inozyme-pharma-inc/increase-decrease-in-accrued-liabilities https://stock.noler.com/us/stock/inozyme-pharma-inc/increase-decrease-in-operating-lease-liability https://stock.noler.com/us/stock/inozyme-pharma-inc/increase-decrease-in-other-noncurrent-liabilities https://stock.noler.com/us/stock/inozyme-pharma-inc/increase-decrease-in-other-operating-assets https://stock.noler.com/us/stock/inozyme-pharma-inc/increase-decrease-in-prepaid-deferred-expense-and-other-assets https://stock.noler.com/us/stock/inozyme-pharma-inc/insider-transactions-preferred https://stock.noler.com/us/stock/inozyme-pharma-inc/insider-transactions-stock-options https://stock.noler.com/us/stock/inozyme-pharma-inc/insider-transactions-stock-units https://stock.noler.com/us/stock/inozyme-pharma-inc/interest-expense https://stock.noler.com/us/stock/inozyme-pharma-inc/interest-expense-nonoperating https://stock.noler.com/us/stock/inozyme-pharma-inc/interest-paid-net https://stock.noler.com/us/stock/inozyme-pharma-inc/interest-receivable-current https://stock.noler.com/us/stock/inozyme-pharma-inc/investing-cash-flow https://stock.noler.com/us/stock/inozyme-pharma-inc/investment-income-interest https://stock.noler.com/us/stock/inozyme-pharma-inc/lease-incentive-receivable https://stock.noler.com/us/stock/inozyme-pharma-inc/legal-fees https://stock.noler.com/us/stock/inozyme-pharma-inc/lessee-operating-lease-liability-payments-remainder-of-fiscal-year https://stock.noler.com/us/stock/inozyme-pharma-inc/lessee-operating-lease-liability-undiscounted-excess-amount https://stock.noler.com/us/stock/inozyme-pharma-inc/level-3-asset-transfers-into-level https://stock.noler.com/us/stock/inozyme-pharma-inc/level-3-asset-transfers-out-of-level https://stock.noler.com/us/stock/inozyme-pharma-inc/line-of-credit-facility-unused-capacity-commitment-fee-percentage https://stock.noler.com/us/stock/inozyme-pharma-inc/long-term-debt-and-capital-lease-obligations-including-current-maturities https://stock.noler.com/us/stock/inozyme-pharma-inc/long-term-investments https://stock.noler.com/us/stock/inozyme-pharma-inc/management-fee-expense https://stock.noler.com/us/stock/inozyme-pharma-inc/net-change-in-cash https://stock.noler.com/us/stock/inozyme-pharma-inc/net-income https://stock.noler.com/us/stock/inozyme-pharma-inc/number-of-operating-segments https://stock.noler.com/us/stock/inozyme-pharma-inc/number-of-reportable-segments https://stock.noler.com/us/stock/inozyme-pharma-inc/oci-available-for-sale-adjustment-net-of-tax https://stock.noler.com/us/stock/inozyme-pharma-inc/oci-foreign-currency-transaction-and-translation-adjustment-before-tax https://stock.noler.com/us/stock/inozyme-pharma-inc/oci-foreign-currency-transaction-and-translation-adjustment-net-of-tax https://stock.noler.com/us/stock/inozyme-pharma-inc/oci-net-of-tax https://stock.noler.com/us/stock/inozyme-pharma-inc/oci-unrealized-holding-gain-loss-on-securities-arising-before-tax https://stock.noler.com/us/stock/inozyme-pharma-inc/operating-cash-flow https://stock.noler.com/us/stock/inozyme-pharma-inc/operating-expenses https://stock.noler.com/us/stock/inozyme-pharma-inc/operating-income https://stock.noler.com/us/stock/inozyme-pharma-inc/operating-lease-assets https://stock.noler.com/us/stock/inozyme-pharma-inc/operating-lease-expense https://stock.noler.com/us/stock/inozyme-pharma-inc/operating-lease-impairment-loss https://stock.noler.com/us/stock/inozyme-pharma-inc/operating-lease-liability https://stock.noler.com/us/stock/inozyme-pharma-inc/operating-lease-liability-current https://stock.noler.com/us/stock/inozyme-pharma-inc/operating-lease-liability-noncurrent https://stock.noler.com/us/stock/inozyme-pharma-inc/operating-lease-payments https://stock.noler.com/us/stock/inozyme-pharma-inc/operating-lease-payments-due https://stock.noler.com/us/stock/inozyme-pharma-inc/operating-lease-payments-due-next-twelve-months https://stock.noler.com/us/stock/inozyme-pharma-inc/operating-lease-payments-due-year-five https://stock.noler.com/us/stock/inozyme-pharma-inc/operating-lease-payments-due-year-four https://stock.noler.com/us/stock/inozyme-pharma-inc/operating-lease-payments-due-year-three https://stock.noler.com/us/stock/inozyme-pharma-inc/operating-lease-payments-due-year-two https://stock.noler.com/us/stock/inozyme-pharma-inc/other-accrued-liabilities-current https://stock.noler.com/us/stock/inozyme-pharma-inc/other-income https://stock.noler.com/us/stock/inozyme-pharma-inc/other-long-term-debt-current https://stock.noler.com/us/stock/inozyme-pharma-inc/other-noncurrent-assets https://stock.noler.com/us/stock/inozyme-pharma-inc/other-noncurrent-liabilities https://stock.noler.com/us/stock/inozyme-pharma-inc/other-nonoperating-income-expense https://stock.noler.com/us/stock/inozyme-pharma-inc/other-prepaid-expense-current https://stock.noler.com/us/stock/inozyme-pharma-inc/paid-in-capital-stock-compensation https://stock.noler.com/us/stock/inozyme-pharma-inc/partners-capital-account-public-sale-of-units-net-of-offering-costs https://stock.noler.com/us/stock/inozyme-pharma-inc/payments-for-repurchase-of-initial-public-offering https://stock.noler.com/us/stock/inozyme-pharma-inc/payments-for-restructuring https://stock.noler.com/us/stock/inozyme-pharma-inc/payments-of-stock-issuance-costs https://stock.noler.com/us/stock/inozyme-pharma-inc/payments-to-acquire-marketable-securities https://stock.noler.com/us/stock/inozyme-pharma-inc/preferred-shares-facts https://stock.noler.com/us/stock/inozyme-pharma-inc/preferred-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/inozyme-pharma-inc/preferred-stock-shares-authorized https://stock.noler.com/us/stock/inozyme-pharma-inc/preferred-stock-shares-issued https://stock.noler.com/us/stock/inozyme-pharma-inc/preferred-stock-shares-outstanding https://stock.noler.com/us/stock/inozyme-pharma-inc/preferred-stock-value https://stock.noler.com/us/stock/inozyme-pharma-inc/prepaid-expense-and-other-assets-current https://stock.noler.com/us/stock/inozyme-pharma-inc/prepaid-expense-noncurrent https://stock.noler.com/us/stock/inozyme-pharma-inc/prepaid-insurance https://stock.noler.com/us/stock/inozyme-pharma-inc/prepaid-taxes https://stock.noler.com/us/stock/inozyme-pharma-inc/proceeds-from-issuance-initial-public-offering https://stock.noler.com/us/stock/inozyme-pharma-inc/proceeds-from-issuance-of-convertible-preferred-stock https://stock.noler.com/us/stock/inozyme-pharma-inc/proceeds-from-issuance-of-warrants https://stock.noler.com/us/stock/inozyme-pharma-inc/proceeds-from-sale-and-maturity-of-marketable-securities https://stock.noler.com/us/stock/inozyme-pharma-inc/proceeds-from-stock-issued https://stock.noler.com/us/stock/inozyme-pharma-inc/proceeds-from-stock-options-exercised https://stock.noler.com/us/stock/inozyme-pharma-inc/profit-loss https://stock.noler.com/us/stock/inozyme-pharma-inc/property-plant-and-equipment-gross https://stock.noler.com/us/stock/inozyme-pharma-inc/property-plant-equipment https://stock.noler.com/us/stock/inozyme-pharma-inc/public-float https://stock.noler.com/us/stock/inozyme-pharma-inc/research-and-development https://stock.noler.com/us/stock/inozyme-pharma-inc/research-and-development-in-process https://stock.noler.com/us/stock/inozyme-pharma-inc/restricted-cash https://stock.noler.com/us/stock/inozyme-pharma-inc/restricted-cash-and-cash-equivalents https://stock.noler.com/us/stock/inozyme-pharma-inc/restricted-cash-noncurrent https://stock.noler.com/us/stock/inozyme-pharma-inc/restructuring-charges https://stock.noler.com/us/stock/inozyme-pharma-inc/restructuring-reserve https://stock.noler.com/us/stock/inozyme-pharma-inc/retained-earnings https://stock.noler.com/us/stock/inozyme-pharma-inc/sale-of-stock-price-per-share https://stock.noler.com/us/stock/inozyme-pharma-inc/security-deposit https://stock.noler.com/us/stock/inozyme-pharma-inc/share-based-goods-and-nonemployee-services-transaction-valuation-method-expected-dividend-rate https://stock.noler.com/us/stock/inozyme-pharma-inc/shareholders-equity https://stock.noler.com/us/stock/inozyme-pharma-inc/shares-authorized https://stock.noler.com/us/stock/inozyme-pharma-inc/shares-issued https://stock.noler.com/us/stock/inozyme-pharma-inc/shares-issued-price-per-share https://stock.noler.com/us/stock/inozyme-pharma-inc/short-term-debt https://stock.noler.com/us/stock/inozyme-pharma-inc/short-term-investments https://stock.noler.com/us/stock/inozyme-pharma-inc/stock-award-fair-value-assumptions-expected-dividend-rate https://stock.noler.com/us/stock/inozyme-pharma-inc/stock-award-fair-value-assumptions-expected-volatility-rate https://stock.noler.com/us/stock/inozyme-pharma-inc/stock-award-fair-value-assumptions-expected-volatility-rate-maximum https://stock.noler.com/us/stock/inozyme-pharma-inc/stock-award-fair-value-assumptions-expected-volatility-rate-minimum https://stock.noler.com/us/stock/inozyme-pharma-inc/stock-award-fair-value-assumptions-risk-free-interest-rate https://stock.noler.com/us/stock/inozyme-pharma-inc/stock-award-fair-value-assumptions-risk-free-interest-rate-maximum https://stock.noler.com/us/stock/inozyme-pharma-inc/stock-award-fair-value-assumptions-risk-free-interest-rate-minimum https://stock.noler.com/us/stock/inozyme-pharma-inc/stock-award-fair-value-assumptions-weighted-average-volatility-rate https://stock.noler.com/us/stock/inozyme-pharma-inc/stock-award-options-exercises-in-period-average-exercise-price https://stock.noler.com/us/stock/inozyme-pharma-inc/stock-award-options-forfeitures-in-period-average-exercise-price https://stock.noler.com/us/stock/inozyme-pharma-inc/stock-award-options-grants-in-period-average-exercise-price https://stock.noler.com/us/stock/inozyme-pharma-inc/stock-based-compensation https://stock.noler.com/us/stock/inozyme-pharma-inc/stock-compensation-unrecognized-cost https://stock.noler.com/us/stock/inozyme-pharma-inc/stock-issued-new-shares-sold https://stock.noler.com/us/stock/inozyme-pharma-inc/stock-issued-shares-issued-for-options-exercised https://stock.noler.com/us/stock/inozyme-pharma-inc/stock-issued-shares-issued-value-conversion-of-convertible-securities https://stock.noler.com/us/stock/inozyme-pharma-inc/stock-issued-shares-issued-value-espp https://stock.noler.com/us/stock/inozyme-pharma-inc/stock-issued-shares-issued-value-stock-options-exercised https://stock.noler.com/us/stock/inozyme-pharma-inc/stock-options-exercisable-average-exercise-price https://stock.noler.com/us/stock/inozyme-pharma-inc/stock-options-exercisable-intrinsic-value https://stock.noler.com/us/stock/inozyme-pharma-inc/stock-options-exercisable-number https://stock.noler.com/us/stock/inozyme-pharma-inc/stock-options-exercises-in-period-total-intrinsic-value https://stock.noler.com/us/stock/inozyme-pharma-inc/stock-options-forfeitures-in-period https://stock.noler.com/us/stock/inozyme-pharma-inc/stock-options-grants-in-period-grant-date-fair-value https://stock.noler.com/us/stock/inozyme-pharma-inc/stock-options-grants-in-period-gross https://stock.noler.com/us/stock/inozyme-pharma-inc/stock-options-outstanding-average-exercise-price https://stock.noler.com/us/stock/inozyme-pharma-inc/stock-options-outstanding-intrinsic-value https://stock.noler.com/us/stock/inozyme-pharma-inc/stock-options-outstanding-number https://stock.noler.com/us/stock/inozyme-pharma-inc/stock-options-vested-and-expected-to-vest-exercisable-aggregate-intrinsic-value https://stock.noler.com/us/stock/inozyme-pharma-inc/stock-options-vested-and-expected-to-vest-outstanding-average-exercise-price https://stock.noler.com/us/stock/inozyme-pharma-inc/stock-options-vested-and-expected-to-vest-outstanding-number https://stock.noler.com/us/stock/inozyme-pharma-inc/stock-options-vested-in-period-fair-value https://stock.noler.com/us/stock/inozyme-pharma-inc/stock-options-vested-number-of-shares https://stock.noler.com/us/stock/inozyme-pharma-inc/stock-split-ratio https://stock.noler.com/us/stock/inozyme-pharma-inc/tax-rate-reconciliation-at-federal-statutory-income-tax-rate https://stock.noler.com/us/stock/inozyme-pharma-inc/tax-rate-reconciliation-change-in-deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/inozyme-pharma-inc/tax-rate-reconciliation-other-adjustments https://stock.noler.com/us/stock/inozyme-pharma-inc/tax-rate-reconciliation-state-and-local-income-taxes https://stock.noler.com/us/stock/inozyme-pharma-inc/tax-rate-reconciliation-tax-credits-research https://stock.noler.com/us/stock/inozyme-pharma-inc/temporary-equity-carrying-amount-attributable-to-parent https://stock.noler.com/us/stock/inozyme-pharma-inc/temporary-equity-liquidation-preference https://stock.noler.com/us/stock/inozyme-pharma-inc/temporary-equity-share-subscriptions https://stock.noler.com/us/stock/inozyme-pharma-inc/temporary-equity-shares-authorized https://stock.noler.com/us/stock/inozyme-pharma-inc/temporary-equity-shares-issued https://stock.noler.com/us/stock/inozyme-pharma-inc/temporary-equity-shares-outstanding https://stock.noler.com/us/stock/inozyme-pharma-inc/total-assets https://stock.noler.com/us/stock/inozyme-pharma-inc/total-liabilities https://stock.noler.com/us/stock/inozyme-pharma-inc/total-liabilities-and-equity https://stock.noler.com/us/stock/inozyme-pharma-inc/total-long-term-debt https://stock.noler.com/us/stock/inozyme-pharma-inc/unrecognized-tax-benefits https://stock.noler.com/us/stock/inozyme-pharma-inc/utb-income-tax-penalties-and-interest-expense https://stock.noler.com/us/stock/inozyme-pharma-inc/valuation-allowance-deferred-tax-asset-change-in-amount https://stock.noler.com/us/stock/inozyme-pharma-inc/weighted-average-number-of-share-outstanding-basic-and-diluted https://stock.noler.com/us/stock/inozyme-pharma-inc/weighted-average-number-of-shares-contingently-issuable